Version 1
: Received: 29 August 2023 / Approved: 30 August 2023 / Online: 31 August 2023 (03:22:20 CEST)
How to cite:
Zhang, R.; Wang, Q.; Zhou, X.; Li, Q.; Dong, Z.; Chen, X. Understanding Proteinuria in Patients with Diabetic Kidney Disease and Progress of Drug Therapy from a New Perspective. Preprints2023, 2023082062. https://doi.org/10.20944/preprints202308.2062.v1
Zhang, R.; Wang, Q.; Zhou, X.; Li, Q.; Dong, Z.; Chen, X. Understanding Proteinuria in Patients with Diabetic Kidney Disease and Progress of Drug Therapy from a New Perspective. Preprints 2023, 2023082062. https://doi.org/10.20944/preprints202308.2062.v1
Zhang, R.; Wang, Q.; Zhou, X.; Li, Q.; Dong, Z.; Chen, X. Understanding Proteinuria in Patients with Diabetic Kidney Disease and Progress of Drug Therapy from a New Perspective. Preprints2023, 2023082062. https://doi.org/10.20944/preprints202308.2062.v1
APA Style
Zhang, R., Wang, Q., Zhou, X., Li, Q., Dong, Z., & Chen, X. (2023). Understanding Proteinuria in Patients with Diabetic Kidney Disease and Progress of Drug Therapy from a New Perspective. Preprints. https://doi.org/10.20944/preprints202308.2062.v1
Chicago/Turabian Style
Zhang, R., Zheyi Dong and Xiangmei Chen. 2023 "Understanding Proteinuria in Patients with Diabetic Kidney Disease and Progress of Drug Therapy from a New Perspective" Preprints. https://doi.org/10.20944/preprints202308.2062.v1
Abstract
Diabetic kidney disease (DKD) is one of the leading causes of end-stage renal disease worldwide and significantly increases the risk of premature death due to cardiovascular diseases. Elevated urinary albumin levels are an important clinical feature of DKD. Effective control of albuminuria not only delays glomerular filtration rate (GFR) decline but also markedly reduces cardiovascular disease risk and all-cause mortality. New drugs for treating DKD proteinuria, including sodium-glucose cotransporter 2 inhibitors (SGLT2i), mineralocorticoid receptor antagonists (MRAs), and endothelin receptor antagonists (REAs), have shown significant efficacy. Auxiliary treatment with proprietary Chinese medicine has also yielded promising results; however, it also faces a broader scope for development. The mechanisms by which these drugs treat albuminuria in patients with DKD should be described more thoroughly. The positive effects of combination therapy with two or more drugs in reducing albuminuria and protecting the kidneys warrant further investigation. Therefore, this review explores the pathophysiological mechanism of albuminuria in patients with DKD, the value of clinical diagnosis and prognosis, new progress and mechanisms of treatment, and multidrug therapy in patients who have type 2 diabetic kidney disease (T2DKD), providing a new perspective on the clinical diagnosis and treatment of DKD.
Keywords
diabetic kidney disease; proteinuria; pathophysiological mechanism; drug therapy
Subject
Medicine and Pharmacology, Endocrinology and Metabolism
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
